A Phase 2, Open-label, Randomized, Parallel Group, Controlled Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus-Positive, Non-Squamous, Non-Small Cell Lung Carcinoma Following First-Line Induction Chemotherapy

Open label
Enrollment in the order of confirmation of eligibility and HPV+ tumor status
Prospective stratification based on 3 factors, epidermal growth factor receptor (EGFR) mutation status, performance status and first-line induction chemotherapy outcome;
Randomization (2:1 ratio): (82 patients receiving the combination of pemetrexed plus ADXS11-001 vs. 42 patients receiving pemetrexed alone)
Treatment Arm: Pemetrexed plus ADXS11-001 immunotherapy
Control Arm: Pemetrexed only
Positive control: pemetrexed chemotherapy

Start Date01 Dec 2018

Sponsor / Collaborator

Advaxis, Inc.

NCT02399813

/ CompletedPhase 2

Phase 2 Study of ADXS11-001 in Subjects With Persistent/Recurrent, Loco-Regional or Metastatic Squamous Cell Carcinoma of the Anorectal Canal

This is a single arm Phase 2 study. Stage 1 and 2 of the study are monotherapy evaluations of ADXS11-001 in 31 and 24 participants, respectively with persistent/recurrent, loco-regional or metastatic squamous cell carcinoma (SCCA) of the anorectal canal that have received at least 1 regimen for the treatment of advanced disease.

Start Date02 Jun 2016

Sponsor / Collaborator

Advaxis, Inc.

NCT02853604

/ TerminatedPhase 3

Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV

Locally advanced cervical cancer at higher risk for recurrence (HRLACC) following concurrent chemotherapy and radiation therapy. This is a group of participants with a significant unmet need. The estimated probability of disease recurrence or death within 4 years of diagnosis is 50% and the prognosis is very grave for those who experience a recurrence.
The purpose of the study was to compare the disease free survival (DFS) of ADXS11-001 to placebo administered following cisplatin-based combination chemotherapy and radiation (CCRT) with curative intent in participants with HRLACC.

Start Date15 Dec 2015

Sponsor / Collaborator

Advaxis, Inc.

[+1]

100 Clinical Results associated with Axalimogene filolisbac

100 Translational Medicine associated with Axalimogene filolisbac

100 Patents (Medical) associated with Axalimogene filolisbac

Literatures (Medical) associated with Axalimogene filolisbac

03 Aug 2021·Human vaccines & immunotherapeuticsQ3 · MEDICINE

ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer

Q3 · MEDICINE

Article

Author: Morán-Mendoza, Andrés ; Cruz-Esquivel, Ivan ; Cetina-Pérez, Lucely ; Castro-Eguiluz, Denisse ; Arango-Bravo, Eder ; Serrano-Olvera, Juan a ; Galicia-Carmona, Tatiana ; Flores-de La Torre, Celia ; Villalobos-Valencia, Ricardo

Human papillomavirus (HPV) infection is a well-known cause of cervical cancer. Therapeutic cancer vaccines are part of the current therapeutic options for HPV-associated cancers. Axalimogen filolisbac (ADXS11-001) is an immunotherapy based on live attenuated Listeria monocytogenes-listeriolysin O (Lm-LLO), designed by biological engineering to secrete an antigen-adjuvant fusion protein, composed of a truncated fragment of LLO fused to HPV. The proposed mechanism of action is that Lm-based vectors infect antigen-presenting cells (APC) and secrete HPV-LLO fusion proteins within the APC cytoplasm, these proteins are processed and presented to cytotoxic T lymphocytes (CTL), thus generating a new population of CTLs specific to HPV antigens. These HPV-specific CTLs destroy HPV infected cells. ADXS11-001 has demonstrated safety results in phase I-II studies in women with cervical cancer and is being assessed in clinical trials in patients with HPV-positive anal canal and head and neck cancers.

01 Sep 2020·Gynecologic oncologyQ2 · MEDICINE

Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study

Q2 · MEDICINE

Article

Author: Tanner, Edward J ; Leath, Charles A ; Aghajanian, Carol ; Brady, William E ; Crane, Erin K ; Fracasso, Paula M ; Landrum, Lisa M ; McHale, Michael T ; Huh, Warner K ; Ueda, Stefanie ; Dizon, Don S ; Powell, Matthew A ; Monk, Bradley J

OBJECTIVE:

Women with persistent, recurrent, and/or metastatic cervical cancer have a poor prognosis. Even with the availability of cisplatin plus paclitaxel and bevacizumab, median overall survival (OS) is only 17.0 months, with median post-progression survival of approximately seven months. We studied the therapeutic vaccine, Axalimogene filolisbac (ADXS-HPV), in women who had progressed following at least one prior line of therapy (Gynecologic Oncology Group protocol 265/NCT01266460).

METHODS:

Volunteers ≥18 years with advanced cervical cancer and GOG performance status score of 0 or 1 were eligible for participation in this 2-stage, phase II trial. In stage 1, women received up to three doses of ADXS-HPV (1 × 10⁹ colony-forming units in 250 mL IV over 15 min every 28 days) and were monitored for tumor progression. In stage 2, women were treated until progression, intolerable adverse events (AEs), or voluntary withdrawal of consent. Co-primary endpoints were safety and proportion of volunteers surviving ≥12 months. An estimated, combined (stages 1 + 2) 12-month OS of 35% was calculated from historical GOG cohorts to declare ADXS-HPV sufficiently active in this platinum-pre-treated population. Secondary endpoints were OS and progression-free survival (PFS).

RESULTS:

Among 50 evaluable volunteers, the 12-month OS was 38% (n = 19). Median OS was 6.1 months (95% CI: 4.3-12.1) and median PFS was 2.8 months (95% CI: 2.6-3.0). The most common treatment-related AEs were fatigue, chills, fever, nausea, and anemia. The majority of AEs were grade 1 or 2 and resolved spontaneously or with appropriate treatment.

CONCLUSION:

At the dose and schedule studied, ADXS-HPV immunotherapy was tolerable and met the protocol-specified benchmark for activity required to warrant further investigation in volunteers with cervical carcinoma.

14 Apr 2020·Oncotarget

A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer

Article

Author: Amin, Manik ; Fakih, Marwan ; Uronis, Hope ; Eng, Cathy ; Hochster, Howard S. ; Boland, Patrick M. ; Morris, Van

Squamous cell carcinoma of the anorectal canal (SCCA) is a rare HPV-related malignancy that is steadily increasing in incidence. A high unmet need exists for patients with persistent loco-regional and metastatic disease. Axalimogene filolisbac (ADXS11-001) is an investigational immunotherapy that stimulates tumor-specific responses against HPV-associated cancers, and has demonstrated benefit in metastatic cervical cancer. We conducted this single-arm, multicenter, phase 2 trial in patients with persistent/recurrent, loco-regional or metastatic SCCA. Patients received ADXS11-001, 1 × 10⁹ colony-forming units intravenously every 3 weeks. A Simon 2-stage design was used to test primary co-endpoints of overall response rate (ORR) and 6-month progression-free survival (PFS) rate. Study would proceed to full enrollment if ORR ≥ 10% or 6-month PFS rate ≥ 20%. Thirty-six patients were treated; 29 patients were evaluable for response. One patient had a prolonged partial response (3.4% ORR). The 6-month PFS rate was 15.5%. Grade 3 adverse event were noted in 10 patients, with the majority being cytokine-release symptoms; one grade 4 adverse event was noted. No grade 5 adverse events occurred. ADXS11-001 was safe and well-tolerated in patients with SCCA. However, this study did not meet either primary endpoint. ADXS11-001 may be more beneficial when administered in combination with other cytotoxic or targeted agents.

News (Medical) associated with Axalimogene filolisbac

15 Jul 2023

·www.prnewswire.com

Anal Cancer Pipeline Insight Research 2023: Focus on 6+ Companies and 8+ Pipeline Drugs Featuring Incyte, Merck, Novartis, & Advaxis

DUBLIN, July 14, 2023 /PRNewswire/ -- The "Anal Cancer - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering. With a focus on 6+ companies and 8+ pipeline drugs, this report provides a detailed analysis of the current scenario and growth prospects across the indication. The report covers an extensive range of pipeline drug profiles, encompassing both clinical and nonclinical stage products. It also provides a comprehensive assessment of therapeutics, including product type, stage, route of administration, and molecule type. Additionally, the report highlights inactive pipeline products in this space, providing a complete overview of the Anal Cancer pipeline landscape. To provide a holistic understanding, the report outlines the present scenario and growth prospects in the field of Anal Cancer. It offers a detailed picture of the Anal Cancer pipeline landscape, including an overview of the disease and treatment guidelines. Furthermore, the report conducts an in-depth assessment of the commercial and clinical aspects of Anal Cancer, evaluating the pipeline products under development. Detailed descriptions of each drug are provided, including their mechanisms of action, clinical studies, NDA approvals (if any), and comprehensive product development activities. This includes technology, Anal Cancer collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant product-related details. Stay ahead of the curve and gain a comprehensive understanding of the latest advancements in Anal Cancer treatment with our in-depth report on the Anal Cancer pipeline landscape. Discover novel approaches and potential breakthroughs that are shaping the future of Anal Cancer therapeutics. Anal Cancer Emerging Drugs Chapters This segment of the Anal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Anal Cancer Emerging Drugs PDS0101: Merck & Co PDS0101 is a novel investigational human papillomavirus (HPV)-targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers. PDS0101 is given by a simple subcutaneous injection in combination with other immunotherapies and cancer treatments. Interim data suggests PDS0101 generates clinically effective immune responses, and the combination of PDS0101 with other treatments demonstrates significant disease control by shrinking tumors, delaying disease progression, and/or prolonging survival. The combination of PDS0101 with other treatments does not appear to compound the toxicity of other agents. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of patients with anal cancer. Avelumab: Merck KGaA Avelumab is a human anti-programmed death ligand-1 (PD-L1) antibody. Avelumab has been shown in preclinical models to engage both the adaptive and innate immune functions. By blocking the interaction of PD-L1 with PD-1 receptors, avelumab has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models. The drug is in phase II of clinical trials for the treatment of anal cancer. Anal Cancer: Therapeutic Assessment Phases Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Molecule Type Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Product Type Anal Cancer Report Insights Anal Cancer Pipeline Analysis Therapeutic Assessment Unmet Needs Impact of Drugs Anal Cancer Report Assessment Pipeline Product Profiles Therapeutic Assessment Pipeline Assessment Inactive drugs assessment Unmet Needs Key Players Incyte Corporation Merck & Co Novartis Pharmaceuticals Advaxis Merck KGaA Key Products Retifanlimab PDS0101 KFA-115 ADXS11-001 Avelumab For more information about this clinical trials report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Phase 2ImmunotherapyGene TherapyASCO

24 Jan 2019

·www.biospace.com

FDA Places Advaxis Cervical Cancer Trial on Clinical Hold

Aligos halted the production of therapy for Chroni No safety issues were cited. Instead, it appears related to the company’s proposal to modify the trial’s analysis plan and various chemistry, manufacturing and controls (CMC) issues. The U.S. Food and Drug Administration (FDA) placed Princeton, NJ-based Advaxis ’ Phase III clinical trial of axalimogene filolisbac (AXAL) in advanced cervical cancer on partial clinical hold. No safety issues were cited. Instead, it appears related to the company’s proposal to modify the trial’s analysis plan and various chemistry, manufacturing and controls (CMC) issues. The trial is an ongoing randomized, double-blinded, placebo-controlled, pivotal trial of AXAL in high-risk, locally advanced cervical cancer (AIM2CERV). The partial hold means no new patients can enroll in the trial until the hold is lifted. “FDA’s review of the AXAL Investigational New Drug (IND) application was prompted by our proposal to modify the AIM2CERV trial’s analysis plan to include, among other things, allowance for a second formal interim analysis for both safety and efficacy,” stated Kenneth A. Berlin , Advaxis’ president and chief executive officer. “The primary focus of the items raised by the Agency relates to providing additional clarifying details for CMC information previously provided in support of Phase III development and which will help support a future Biologics License Application.” Berlin went on to say that they have already started on responding to the FDA. “Our AXAL product has demonstrated a manageable safety pro the over 400 patients we have dosed to date and we look forward to enrolling new patients in our AIM2CERV trial after FDA agrees that the information we submit is responsive to its requests.” Cervical cancer is the most common human papilloma virus (HPV)-associated cancer in women. Each year, about 4,210 women die from cervical cancer in the U.S. There are slightly under 13,000 newly diagnosed cases each year. AXAL has shown in earlier trials and preclinical studies to alert the body’s immune system to the presence of the cancer and reduce the cancer’s natural defenses, then stimulate the body’s killer T-cells to attack the cancer. AXAL targets HPV-associated cancers. The FDA has given it orphan drug designation and a Special Protocol Assessment for the Phase III AIM2CERV trial, as well as Fast Track Designation. The company’s technology uses live attenuated Listeria monocytogenes engineered to produce antigen-adjuvant fusion proteins. This is only the most recent setback Advaxis has faced. In mid-December 2018, Amgen walked away from an immuno-oncology partnership the two companies had. The companies were working to develop ADX-NEO, a preclinical program that used Advaxis’ Listeria monocytogenes bacterial vector. The partnership was going to end Feb. 8, 2019. It began in 2016 and was valued at up to $540 million. Amgen paid $40 million up front and acquired $25 million of Advaxis common stock at the time. In the filing with the U.S. Securities and Exchange Commission, Advaxis indicated it had received reimbursement payments of $5.8 million and $7.5 million related to the deal. In March 2018, the FDA halted a clinical trial of AXAL with AstraZeneca ’s Imfinzi (durvalumab) for advanced, recurrent or refractory cervical cancer and HPV-associated head and neck cancer. This followed the death of a patient. The patient died from respiratory failure nine months after receiving the combination treatment. The hold was lifted in July. To lift that hold, the FDA and Advaxis developed new guidelines for the trial that assisted with the early detection and treatment of “such rare events.” But in November, the company announced it would halt enrollment in the Phase I/II trial combining AXAL and Imfinzi in order to “maximize the efficient use of clinical funding resources.”

Phase 3Fast Track

14 Dec 2018

·www.biospace.com

Amgen Terminates $540 Million Developmental Deal with Advaxis

end of relations(special f/x,made from my images) Kuzma/Getty Images/iStockphoto Shares of New Jersey-based Advaxis have plunged more than 28 percent in premarket trading after the company quietly disclosed that Amgen terminated its collaboration on an immuno-oncology program. The deal between the two companies was first inked in 2016 and had a value of up to $540 million. Shares of New Jersey-based Advaxis have plunged more than 28 percent in premarket trading after the company quietly disclosed that Amgen terminated its collaboration on an immuno-oncology program. In a filing with the U.S. Securities and Exchange Commission, Advaxis said Amgen issued a written notice that it will withdraw its partnership on the development of ADX-NEO, a preclinical program that uses Advaxis’ proprietary Listeria monocytogenes attenuated bacterial vector. The vector is designed to activate a patient’s immune system to respond to unique mutations or neoepitopes. The partnership with Amgen is set to end Feb. 8, 2019. Advaxis said it is currently enrolling patients for an early-stage trial and will have to evaluate whether or not to find a new developmental partner for the ADX-NEO program. The deal between the two companies was first inked in 2016 and had a value of up to $540 million. Amgen made a $40 million upfront payment and purchased $25 million of Advaxis common stock as part of the deal. Advaxis had been leading the clinical development of ADXS-NEO through proof-of-concept. Over the past fiscal year, Advaxis said in its filing that it has received reimbursement payments of $5.8 million and $7.5 million, respectively, related to the Amgen agreement. No reason was provided for the termination of the agreement. As expected, shares of Advaxis took a hit following the announcement. The stock fell to 11 cents per share in premarket trading. It closed at 38 cents per share on Thursday. Amgen’s decision to walk away from the deal with Advaxis is the latest blow to the company and its investors. In March the U.S. Food and Drug Administration halted a clinical trial on a cancer study. The trial was studying a combination of Advaxis’ axalimogene filolisbac (AXAL) with AstraZeneca’s Imfinzi (durvalumab) in the treatment of advanced, recurrent or refractory cervical cancer and HPV-associated head and neck cancer. The trial was halted by the FDA following the death of a patient. The patient died as a result of respiratory failure nine months after being dosed with the combination treatment. The hold was lifted in July . To lift the hold, the FDA and Advaxis agreed to new guidelines for the study that will assist with the early detection and treatment of “such rare events.” However, in November, Advaxis announced that it would not continue enrollment in the Phase I/II study combining AXAL and Imfinzi in order to “maximize the efficient use of clinical funding resources.” Also in November, Advaxis said it planned to continue a Phase III trial with AXAL in high-risk, locally advanced cervical cancer (AIM2CERV). The company said at the time that it is evaluating the possibility of accelerating the timeline for the interim analysis of safety and efficacy, as well as establish a “more stringent futility boundary” for the study. Advaxis said over the next several of months it planned to finalize the redesign of the trial and review it with the FDA. Advaxis Chief Executive Officer Kenneth Berlin said the company has become “increasingly optimistic about the prospects” of that study. “The redesign of AIM2CERV with an earlier interim analysis would allow us to alter course or, if necessary, stop the study, depending on the results. If the FDA accepts our proposed revisions, we anticipate having a recommendation based on the interim analysis from the data monitoring committee as early as the fourth quarter of 2020,” Berlin said in November.

Phase 3License out/in

100 Deals associated with Axalimogene filolisbac

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Cervical Carcinoma	Phase 3	United States	Advaxis, Inc.	15 Dec 2015
Locally Advanced Cervical Carcinoma	Phase 3	Argentina	Advaxis, Inc.	15 Dec 2015
Locally Advanced Cervical Carcinoma	Phase 3	Brazil	Advaxis, Inc.	15 Dec 2015
Locally Advanced Cervical Carcinoma	Phase 3	Canada	Advaxis, Inc.	15 Dec 2015
Locally Advanced Cervical Carcinoma	Phase 3	Chile	Advaxis, Inc.	15 Dec 2015
Locally Advanced Cervical Carcinoma	Phase 3	Malaysia	Advaxis, Inc.	15 Dec 2015
Locally Advanced Cervical Carcinoma	Phase 3	Mexico	Advaxis, Inc.	15 Dec 2015
Locally Advanced Cervical Carcinoma	Phase 3	Poland	Advaxis, Inc.	15 Dec 2015
Locally Advanced Cervical Carcinoma	Phase 3	Russia	Advaxis, Inc.	15 Dec 2015
Locally Advanced Cervical Carcinoma	Phase 3	Serbia	Advaxis, Inc.	15 Dec 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02164461 (Phase I, CTgov)	Phase 1	Recurrent Cervical Cancer \| Small Cell Carcinoma \| Adenosquamous Carcinoma ... View more	12	Axalimogene filolisbac (Axalimogene Filolisbac 1x10^9 Cfu)	pvrokjaujr = nmvustpcua ugehtbpofm (vndpuplztw, nkkbsjdtca - kvglomwnrz) View more	-	20 May 2024
NCT02164461 (Phase I, CTgov)	Phase 1		12	Axalimogene filolisbac (Axalimogene Filolisbac 5x10^9 Cfu)	pvrokjaujr = vizazjjjyo ugehtbpofm (vndpuplztw, vroxvznvbd - thwweqfgho) View more	-	20 May 2024
NCT02291055 (P241, CTgov)	Phase 1/2	Squamous cell carcinoma of head and neck metastatic \| Recurrent Cervical Cancer \| Squamous Cell Carcinoma of Head and Neck ... View more	75	MEDI4736+ADXS11-001 (Part A Escalation (Cervical): 1×10^9 CFU ADXS11-001/ 3 mg/kg MEDI4736)	qrulpfoowf = nuiwlzasse smplbugubj (xsjxidfewx, dmqsooumsv - axeoiltbve) View more	-	20 Mar 2023
NCT02291055 (P241, CTgov)	Phase 1/2		75	MEDI4736+ADXS11-001 (Part A Escalation (Cervical and Head and Neck): 1×10^9 CFU ADXS11-001/ 10 mg/kg MEDI4736)	qrulpfoowf = nemixeocwz smplbugubj (xsjxidfewx, oiiuoluguh - xmtnhfjzen) View more	-	20 Mar 2023
NCT02399813 (CTgov)	Phase 2	Anal Canal Carcinoma \| Squamous cell carcinoma, metastatic	36	Axalimogene filolisbac	thnpzdzxfa = gwjwehyyhp ruwcepwjfd (yjuecxkqyh, baactjicgh - wgtfhsmtaq) View more	-	20 Mar 2023
NCT02853604 (AIM2CERV, CTgov)	Phase 3	Locally Advanced Cervical Carcinoma	110	Placebo (Placebo)	eigdxrllfh = pnvjrhcjwz wwahecculn (jvslpbbqwz, lxvkzspzje - cuntaogbsi) View more	-	14 Mar 2023
NCT02853604 (AIM2CERV, CTgov)	Phase 3	Locally Advanced Cervical Carcinoma	110	ADXS11-001 (ADXS11-001)	eigdxrllfh = uxanhcezuv wwahecculn (jvslpbbqwz, jinnuanoyo - olxckgcmlj) View more	-	14 Mar 2023
NCT01266460 (Gynecologic Oncology Group protocol 265 \| GOG/NRG0265, CTgov)	Phase 2	Recurrent Cervical Cancer \| Adenosquamous Carcinoma \| Cervical Squamous Cell Carcinoma ... View more	54	Laboratory Biomarker Analysis+Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001	rvtsriwjrr = kudykidzjz plisrcckbf (dqbvzyaayu, bwsfakmhkj - wxfvciffuw) View more	-	11 Sep 2020
NCT02399813 (Pubmed) Manual	Phase 2	Anus Neoplasms	29	axalimogene filolisbac	ayswxzzsgq(uffdptwaif) = kjavtwgeah pvbyktntrf (izywcoemhv ) View more	Negative	14 Apr 2020
AACR2018	Not Applicable	HPV16 positive Oropharyngeal Cancer	8	ADXS11-001	mfknjcpues(oickyjufan) = rljbyzmems mgequinykc (fejyrxvyrg ) View more	-	01 Jul 2018
NCT01266460 (GOG/NRG0265, ASCO2016)	Phase 2	Uterine Cervical Cancer Maintenance	29	ADXS11-001	vclpwpuclt(hnsiatvjoa) = bcjoafnnkp ekpnivnsag (wsqcujpwsu ) View more	Positive	20 May 2016
NCT02164461 (Phase I, SITC2015)	Phase 1	Uterine Cervical Cancer HPV-E7 tumor antigen	6	ADXS11-001 5x10^9 CFU	yrvcpjbzng(dicwaqusel) = ncmqekwenh cjxzhefvoo (dtshinqypk ) View more	Positive	04 Nov 2015
AACR2015	Phase 1	Osteosarcoma	10	Lm-LLO-HER2/neu	agvjvthrfi(ktjarwbhes) = ukktcdmqfh gimlcxbzib (tpqxucbdgu ) View more	-	01 Aug 2015

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Axalimogene filolisbac

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation